Drugs / ADC189
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06589635 | Jul → Sep 2024 | — | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06485401 | Mar → Jun 2024 | influenza | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06428903 | Mar → Sep 2024 | — | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06360796 | Nov 2023 → Feb 2024 | — | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT06342921 | Dec 2022 → Oct 2023 | — | Jiaxing AnDiCon Biotech Co.,Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-06 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Positive Results from Phase III Clinical Study of Deunoxavir Marboxil Tablets, an Innovative Anti-influenza Drug Collaborated by Simcere Pharmaceuticals and AnDiCon Biotech simcere.com ↗
the Phase III clinical trial of their anti-influenza innovative drug, Deunoxavir Marboxil Tablets (ADC189), has achieved its primary endpoint with significant efficacy and safety results. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-06 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Positive Results from Phase III Clinical Study of Deunoxavir Marboxil Tablets, an Innovative Anti-influenza Drug Collaborated by Simcere Pharmaceuticals and AnDiCon Biotech simcere.com ↗ |
| 2023-10-10 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Pharmaceutical Enters into a Cooperation Agreement with AnDiCon on Anti-influenza Innovative Drug ADC189 simcere.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADC-189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589635 ↗ |
| Known as | almonertinib | “This study is designed to determined the metabolism, excretion, and substance balance of almonertinib of ADC189.” NCT06360796 ↗ |
| Route | Oral | “Oral ADC189 for adults and adolescents with uncomplicated influenza.” PMID 40089214 ↗ Mar 2025 |